Findings from a recent study showed potential associations between psoriasis, comorbid conditions, and sexual and erectile dysfunction among patients with this skin condition.

FDA Alerts

FDA Alerts
Monday, April 25, 2016
Ixekizumab (Taltz, Eli Lilly and Company) received FDA approval as a new treatment for moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy or a combination of both therapies.
FDA Alerts
Wednesday, March 23, 2016
Ixekizumab (Taltz, Eli Lilly and Company) received FDA approval as a new treatment for moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy, or a combination of both therapies.
FDA Alerts
Monday, February 8, 2016
A new prescription topical steroid has received FDA approval for the treatment of mild to moderate plaque psoriasis in patients 18 years of age or older. Betamethasone dipropionate (Sernivo) Spray, 0.05%, from Promius Pharma, LLC, US, a subsidiary of Dr. Reddy’s, will be available next quarter.
FDA Alerts
Saturday, January 16, 2016
The FDA recently approved secukinumab (Cosentyx) for 2 new indications for the treatment of adult patients with active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA).

News

News
Tuesday, April 17, 2018
In a phase 3 trial, researchers investigated the efficacy of a subcutaneous biologic compared with placebo among participants with active psoriatic arthritis. For details from the study, read more.
News
Friday, April 13, 2018
Two phase 3 trials reported on the efficacy and safety of an investigational topical psoriasis treatment in the Journal of the American Academy of Dermatology. For details from the study, read more.
News
Monday, April 2, 2018
Dr Joel Gelfand, professor of dermatology at the University of Pennsylvania Perelman School of Medicine, discusses his latest research on psoriasis and diabetes with Amanda Balbi, managing editor of our sister publication, Consultant360.
News
Friday, March 23, 2018
In a recent study, researchers investigated the long-term efficacy of a psoriasis therapy following withdrawal of treatment among patients with moderate to severe plaque psoriasis.

NPF Endorsed Articles

NPF Endorsed Articles
Monday, April 6, 2015
Here’s a wrap up of several newly published studies on psoriasis.
NPF Endorsed Articles
Wednesday, March 18, 2015
A new independent US psoriasis registry — a joint collaboration with the National Psoriasis Foundation and Corrona, LLC — will allow people with psoriasis and their healthcare providers to participate in research that aims to improve treatments and disease outcomes.
NPF Endorsed Articles
Tuesday, February 24, 2015
Phototherapy is a safe and effective treatment option for psoriasis. Clinicians should consider phototherapy as a first-line treatment for many patients as well as adjunctive therapy for those who fail to respond to other treatment modalities.  
NPF Endorsed Articles
Tuesday, February 3, 2015
Safe and effective long-term therapy is important when treating patients with psoriasis and maintaining remission of this condition.

Research in Review

Research in Review
Saturday, October 15, 2016
Michael Siegel, PhD, of the National Psoriasis Foundation, talks with The Dermatologist about the Foundation’s ongoing efforts in psoriatic disease.
Research in Review
Monday, August 22, 2016
Get a better understanding of psoriasis with The Dermatologist's Psoriasis Fast Facts.
Research in Review
Wednesday, August 10, 2016
A 42-year-old woman with psoriasis presented for evaluation of a new-onset rash of 1 to 2 weeks’ duration on her trunk and extremities.